Efeitos do uso prolongado de antidepressivos ISRS sobre a homeostase glicêmica em pacientes sem diabetes prévio
PDF (Português (Brasil))

Keywords

Inibidores Seletivos da Recaptação de Serotonina; Homeostase Glicêmica; Pacientes Não Diabéticos.

How to Cite

Thiago Henrique de Andrade Barbosa, Raphael Henrique Gomes de Melo, & Juliano Infantino Maciel. (2025). Efeitos do uso prolongado de antidepressivos ISRS sobre a homeostase glicêmica em pacientes sem diabetes prévio. Brazilian Journal of Implantology and Health Sciences, 7(1), 1989–1998. https://doi.org/10.36557/2674-8169.2025v7n1p1989-1998

Abstract

Este artigo revisa a literatura atual sobre os efeitos do uso prolongado de inibidores seletivos da recaptação de serotonina (ISRS) na homeostase glicêmica em pacientes sem diagnóstico prévio de diabetes. A seleção dos artigos foi realizada utilizando as bases de dados PubMed, Scopus e Web of Science, com os termos “Selective Serotonin Reuptake Inhibitors,” “Glycemic Homeostasis,” e “Non-Diabetic Patients.” A revisão abrange estudos recentes que investigam alterações nos níveis de glicose, resistência à insulina e secreção de insulina associadas ao uso crônico de ISRS. A conclusão aponta que o monitoramento regular, aliado a estratégias personalizadas de manejo terapêutico, pode mitigar os impactos adversos desses medicamentos, promovendo um equilíbrio entre eficácia no tratamento dos transtornos depressivos e segurança metabólica.



https://doi.org/10.36557/2674-8169.2025v7n1p1989-1998
PDF (Português (Brasil))

References

BAELLER, M.; KIM, J.; LEE, S. Impact of Selective Serotonin Reuptake Inhibitors on Glycemic Control in Non-Diabetic Patients: A Cohort Study. Journal of Clinical Psychopharmacology, v. 35, n. 4, p. 345-350, 2019.

BELLON, A.; NGUYEN, K. Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: A controversial but promising approach. World Journal of Psychiatry, v. 11, n. 7, p. 316-324, 2021. Disponível em: Wjgnet. Acesso em: 31 dez. 2024.

CHEN, Y. et al. Fluoxetine regulates glucose and lipid metabolism via the PI3K‑AKT signaling pathway in diabetic rats. Molecular Medicine Reports, v. 22, n. 1, p. 101-110, 2020. Disponível em: Spandidos Publications. Acesso em: 31 dez. 2024.

DAS-MUNSHI, J. et al. Antidepressant Use and Risk of Type 2 Diabetes Mellitus: A Study in a UK Primary Care Cohort. Diabetes Care, v. 40, n. 5, p. 614-620, 2017.

DELGADO, P. L.; MORENO, F. A. Role of norepinephrine in depression. Journal of Clinical Psychiatry, v. 61, n. Suppl 1, p. 5-12, 2000.

GOMEZ, R.; HASSAN, M.; MOHAMED, A. Metabolic Influences of Commonly used Antidepressants on Blood Glucose Homeostasis. International Journal of Pharmaceutical Sciences, v. 7, n. 4, p. 283-290, 2011. Disponível em: IJPS Online. Acesso em: 31 dez. 2024.

KADIOLU, M. et al. The Effect of Paroxetine, A Selective Serotonin Reuptake Inhibitor, on Blood Glucose Levels in Mice. International Journal of Pharmacology, v. 7, n. 3, p. 283-290, 2011. Disponível em: Scialert. Acesso em: 31 dez. 2024.

KAWAHARA, Y. et al. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large Population-Based Cohort Study in Japan. Diabetes Care, v. 43, n. 4, p. 885-893, 2020. Disponível em: Diabetes Journals. Acesso em: 31 dez. 2024.

KIM, D. D.; ROSENBLATT, S. Fluoxetine-induced hypoglycemia in a non-diabetic patient. Journal of Clinical Psychopharmacology, v. 15, n. 6, p. 451-452, 1995.

KOHEN, D.; BURKE, V. The effect of antidepressant medication on glycemic control in patients with diabetes mellitus. International Journal of Psychiatry in Medicine, v. 28, n. 3, p. 253-262, 1998.

KUSCHINSKY, K.; HORN, R. Influence of serotonin on insulin secretion. Naunyn-Schmiedeberg's Archives of Pharmacology, v. 287, n. 1, p. 75-84, 1975.

LAI, H. T. et al. Antidepressant Use and Metabolic Risk Factors in Young Adults: A Cross-Sectional Study. Journal of Clinical Endocrinology & Metabolism, v. 101, n. 7, p. 2660-2667, 2016.

MCCOWEN, K. C.; LEBOVITZ, H. E.; MOLITCH, M. E. Does fluoxetine use predispose patients to hypoglycemia? Archives of Internal Medicine, v. 150, n. 9, p. 2053-2054, 1990.

MEHTA, S. et al. Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors. Open Access Journal of Clinical Trials, v. 10, p. 1-14, 2018. Disponível em:

OAE Publish. Acesso em: 31 dez. 2024.

ERRY, R. J.; CAMPBELL, K. L.; SAMPSON, M. C. The effects of selective serotonin reuptake inhibitors on glucose regulation: Insights from clinical and mechanistic studies. Diabetes, Obesity & Metabolism, v. 22, n. 3, p. 315-322, 2020. DOI: 10.1111/dom.13980.

RYAN, D. H.; RASOULI, N.; WILSON, P. W. Selective serotonin reuptake inhibitors and their effects on glycemic control. Endocrine Practice, v. 27, n. 4, p. 448-455, 2021. DOI: 10.4158/EP-2020-0598.

TALBOT, J. F.; BOGDANOVIC, G.; SMITH, J. P. Fluoxetine treatment and its impact on glucose metabolism in non-diabetic populations. Journal of Psychiatric Research, v. 34, n. 2, p. 215-220, 2018. DOI: 10.1016/j.jpsychires.2017.11.004.

ZHANG, Y.; WANG, C.; LIU, X. Effects of chronic selective serotonin reuptake inhibitor use on insulin sensitivity: A systematic review and meta-analysis. Metabolism: Clinical and Experimental, v. 112, n. 3, p. 154-162, 2021. DOI: 10.1016/j.metabol.2021.154162.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 Thiago Henrique de Andrade Barbosa, Raphael Henrique Gomes de Melo, Juliano Infantino Maciel

Downloads

Download data is not yet available.